Omalizumab Dose Step-Up and Treatment Response in Patients with Chronic Idiopathic/Spontaneous Urticaria (CIU/CSU): Results from the OPTIMA Study
نویسندگان
چکیده
منابع مشابه
Effects of Omalizumab Treatment in Patients With Refractory Chronic Urticaria
PURPOSE Chronic urticaria (CU) is a common and debilitating disease, and the need for effective treatment has increased. Omalizumab may be an alternative regimen in patients with CU who do not respond to conventional treatments. The aim of this study is to investigate the efficacy and to observe the clinical results of omlizumab in patients with refractory CU. METHODS We conducted a retrospec...
متن کاملChronic idiopathic urticaria: treatment with omalizumab.
Chronic idiopathic urticaria (CIU) is a common autoimmune skin condition characterized by spontaneously recurring hives for 6 weeks or longer. The new terminology used for CIU in most countries including Canada is chronic spontaneous urticaria (CSU). CSU is associated with significant psychosocial morbidity with a markedly negative impact on overall quality of life. Conventional approaches with...
متن کاملOmalizumab in the treatment of chronic urticaria.
Omalizumab is a monoclonal anti-immunoglobulin E antibody currently only approved for use in severe, refractory asthma. In recent years, many authors have reported satisfactory results with omalizumab in patients with difficult-to-treat chronic urticaria. As a result, clinical trials were undertaken to broaden the indication of omalizumab to include chronic urticaria, and the drug was recently ...
متن کاملadverse reaction to omalizumab in patients with chronic urticaria: flare up or ineffectiveness?
omalizumab is a recombinant humanized anti-ig e monoclonal antibody used as the third line treatment of chronic spontaneous urticaria (csu). we report four patients with severe antihistamine-resistant csu, who developed angioedema, anaphylaxis and/or flare up of urticaria at different times following omalizumab therapy.
متن کاملUse of omalizumab in the treatment of chronic urticaria.
BACKGROUND Omalizumab is indicated to treat chronic spontaneous urticaria (CSU) refractory to antihistamines. We aim to describe the experience of our department in the treatment of CSU with omalizumab. MATERIALS AND METHODS Retrospective review of the clinical records of patients. RESULTS Six patients (5 females, median age 33 years) treated with omalizumab for a median of 17.5 months were...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: SKIN The Journal of Cutaneous Medicine
سال: 2018
ISSN: 2574-1624
DOI: 10.25251/skin.2.supp.52